TRACON Pharmaceuticals Company Leadership
TCON Stock | USD 0.41 0.02 4.65% |
TRACON Pharmaceuticals employs about 17 people. The company is managed by 20 executives with a total tenure of roughly 122 years, averaging almost 6.0 years of service per executive, having 0.85 employees per reported executive. Analysis of TRACON Pharmaceuticals' management performance can provide insight into the firm performance.
Charles Theuer CEO President CEO, Director |
Bonne Adams President Senior Vice President - Clinical Operations |
TRACON |
TRACON Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.2916) % which means that it has lost $0.2916 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.7701) %, meaning that it created substantial loss on money invested by shareholders. TRACON Pharmaceuticals' management efficiency ratios could be used to measure how well TRACON Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, TRACON Pharmaceuticals' Return On Capital Employed is very stable compared to the past year. As of the 28th of March 2024, Return On Equity is likely to grow to 4.66, while Return On Assets are likely to drop (0.37). At this time, TRACON Pharmaceuticals' Other Current Assets are very stable compared to the past year. As of the 28th of March 2024, Asset Turnover is likely to grow to 1.13, while Total Assets are likely to drop about 9.6 M.As of the 28th of March 2024, Common Stock Shares Outstanding is likely to grow to about 34.4 M, while Net Loss is likely to drop (27.5 M).
TRACON Pharmaceuticals Workforce Comparison
TRACON Pharmaceuticals is rated third in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 17,817. TRACON Pharmaceuticals adds roughly 17.0 in number of employees claiming only tiny portion of equities under Health Care industry.
TRACON Pharmaceuticals Profit Margins
The company has Profit Margin (PM) of (0.3) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.13 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.13.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.78 | 0.9 |
|
|
TRACON Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific TRACON Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on TRACON Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, TRACON Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Charles Theuer 3 days ago Acquisition by Charles Theuer of 3500 shares of TRACON Pharmaceuticals at 0.1333 subject to Rule 16b-3 | ||
Charles Theuer over two weeks ago Acquisition by Charles Theuer of 518300 shares of TRACON Pharmaceuticals at 0. subject to Rule 16b-3 | ||
Charles Theuer over two weeks ago Acquisition by Charles Theuer of 4500 shares of TRACON Pharmaceuticals at 1.85 subject to Rule 16b-3 | ||
Charles Theuer over six months ago Purchase by Charles Theuer of 99 shares of TRACON Pharmaceuticals | ||
Twiford J Rainer over six months ago Acquisition by Twiford J Rainer of 18000 shares of TRACON Pharmaceuticals subject to Rule 16b-3 | ||
Charles Theuer over a year ago Purchase by Charles Theuer of 200 shares of TRACON Pharmaceuticals | ||
Charles Theuer over a year ago Acquisition by Charles Theuer of 332000 shares of TRACON Pharmaceuticals subject to Rule 16b-3 |
TRACON Pharmaceuticals Notable Stakeholders
A TRACON Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as TRACON Pharmaceuticals often face trade-offs trying to please all of them. TRACON Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting TRACON Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Charles Theuer | President CEO, Director | Profile | |
Bonne Adams | Senior Vice President - Clinical Operations | Profile | |
Patricia Bitar | CFO | Profile | |
Sharon Real | Sr. VP of Product Devel. | Profile | |
Theodore Wang | Director | Profile | |
Martin Mattingly | Independent Director | Profile | |
William LaRue | Independent Director | Profile | |
Alfred Scheidegger | Independent Director | Profile | |
Paul Walker | Independent Director | Profile | |
Stephen Worland | Director | Profile | |
Ted Wang | Director | Profile | |
Rainer Twiford | Independent Director | Profile | |
Pharmd PharmD | VP Affairs | Profile | |
H Logan | Chief Business Officer | Profile | |
James Freddo | Chief Officer | Profile | |
Ronald Shazer | Chief Medical Officer | Profile | |
Shahe Garabedian | Senior Assurance | Profile | |
Mark Wiggins | Chief Business Officer | Profile | |
Ya Huang | Executive Programming | Profile | |
MS CPA | Chief Officer | Profile |
About TRACON Pharmaceuticals Management Performance
The success or failure of an entity such as TRACON Pharmaceuticals often depends on how effective the management is. TRACON Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of TRACON management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the TRACON management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for 2024 | ||
Return On Capital Employed | 89.58 | 94.06 | |
Return On Assets | (0.36) | (0.37) | |
Return On Equity | 4.44 | 4.66 |
The data published in TRACON Pharmaceuticals' official financial statements usually reflect TRACON Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of TRACON Pharmaceuticals. For example, before you start analyzing numbers published by TRACON accountants, it's critical to develop an understanding of what TRACON Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of TRACON Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, TRACON Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in TRACON Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of TRACON Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of TRACON Pharmaceuticals' management manipulating its earnings.
TRACON Pharmaceuticals Workforce Analysis
Traditionally, organizations such as TRACON Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare TRACON Pharmaceuticals within its industry.TRACON Pharmaceuticals Manpower Efficiency
Return on TRACON Pharmaceuticals Manpower
Revenue Per Employee | 708.5K | |
Revenue Per Executive | 602.2K | |
Net Loss Per Employee | 211.1K | |
Net Loss Per Executive | 179.4K |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TRACON Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TRACON Stock, please use our How to Invest in TRACON Pharmaceuticals guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for TRACON Stock analysis
When running TRACON Pharmaceuticals' price analysis, check to measure TRACON Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TRACON Pharmaceuticals is operating at the current time. Most of TRACON Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of TRACON Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TRACON Pharmaceuticals' price. Additionally, you may evaluate how the addition of TRACON Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is TRACON Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TRACON Pharmaceuticals. If investors know TRACON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TRACON Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.11) | Revenue Per Share 0.368 | Return On Assets (0.29) | Return On Equity (12.77) |
The market value of TRACON Pharmaceuticals is measured differently than its book value, which is the value of TRACON that is recorded on the company's balance sheet. Investors also form their own opinion of TRACON Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is TRACON Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TRACON Pharmaceuticals' market value can be influenced by many factors that don't directly affect TRACON Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TRACON Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if TRACON Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TRACON Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.